Phosphatidylinositol 3-kinase γ is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning

Circulation Research

Volumn 103, Issue 6, 2008, Pages 643-653

  Ban, Kiwon ^a,c   Cooper, Andrew J ^a   Samuel, Sara ^c   Bhatti, Adil ^c   Patel, Mikin ^a   Izumo, Seigo ^d   Penninger, Josef M ^e   Backx, Peter H ^a,b   Oudit, Gavin Y ^a,b,f   Tsushima, Robert G ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YORK UNIVERSITY   (Canada)

^d Novartis Institutes for BioMedical Research   (Switzerland)

^e ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Akt; GSK3; Heart; Ischemic preconditioning; PI3K; Transgenic mice

Indexed keywords

ADENOSINE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; PROTEIN P110; UNCLASSIFIED DRUG; WORTMANNIN; ISOENZYME; PHOSPHATIDYLINOSITOL 3-KINASE GAMMA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOBLOTTING; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPERFUSION; TISSUE INJURY; WILD TYPE; ANIMAL; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEART INFARCTION PREVENTION; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE; ANIMALS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; ISOENZYMES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 53249113791     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.175018     Document Type: Article

References (41)

1. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151.
2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
3. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006;70:240-253.
4. Naga Prasad SV, Perrino C, Rockman HA. Role of phosphoinositide 3-kinase in cardiac function and heart failure. Trends Cardiovasc Med. 2003;13:206-212.
5. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2003;37:449-471.
6. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7:606-619.
7. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 2000;19:2537-2548.
8. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, Sasaki T, Hirsch E, Suzuki A, Shioi T, Irie-Sasaki J, Sah R, Cheng HY, Rybin VO, Lembo G, Fratta L, Oliveira-dos-Santos AJ, Benovic JL, Kahn CR, Izumo S, Steinberg SF, Wymann MP, Backx PH, Penninger JM. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell. 2002;110:737-749.
9. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2005;15:69-75.
10. Baines CP, Wang L, Cohen MV, Downey JM. Myocardial protection by insulin is dependent on phosphatidylinositol 3-kinase but not protein kinase C or KATP channels in the isolated rabbit heart. Basic Res Cardiol. 1999;94:188-198.
11. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000;87:309-315.
12. Tong H, Imahashi K, Steenbergen C, Murphy E. Phosphorylation of glycogen synthase kinase-3b during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ Res. 2002;90:377-379.
13. Mocanu MM, Bell RM, Yellon DM. PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol. 2002;34:661-668.
14. Sumeray MS, Yellon DM. Characterisation and validation of a murine model of global ischaemia-reperfusion injury. Mol Cell Biochem. 1998; 186:61-68.
15. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res. 2004;63:305-312.
16. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Ba. Curr Biol. 1997;7:261-269.
17. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT. Protein kinase B kinases that mediate phosphatidyl-inositol 3,4,5-trisphosphate- dependent activation of protein kinase B. Science. 1998;279:710-714.
18. Budas GR, Sukhodub A, Alessi DR, Jovanoviæ A. 3'Phosphoinositide- dependent kinase-1 is essential for ischemic preconditioning of the myocardium. FASEB J. 2006;20:2556-2558.
19. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
20. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, Ziman BD, Wang S, Ytrehus K, Antos CL, Olson EN, Sollott SJ. Glycogen synthase kinase-3b mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549.
21. Pullen N, Dennis PB, Andjelkovic M, Dufner A, Kozma SC, Hemmings BA, Thomas G. Phosphorylation and activation of p70s6k by PDK1. Science. 1998;279:707-710.
22. Alessi DR, Kozlowski MT, Weng QP, Morrice N, Avruch J. 3-Phospho-inositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro. Curr Biol. 1998;8:69-81.
23. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376: 599-602.
24. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. J Biol Chem. 2003;278:33067-33077.
25. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation. 2001; 104:2981-2989.
26. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
27. Sun H, Oudit GY, Ramirez RJ, Costantini D, Backx PH. The phospho-inositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of IKslow currents. Cardiovasc Res. 2004; 62:509-520.
28. El-Kholy W, Macdonald PE, Lin JH, Wang J, Fox JM, Light PE, Wang Q, Tsushima RG, Wheeler MB. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks KV currents via a direct mechanism. FASEB J. 2003;17:720-722.
29. Tong H, Rockman HA, Koch WJ, Steenbergen C, Murphy E. G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res. 2004;94:1133-1141.
30. Matsui T, Li L, del MonteF, Fukui Y, Franke TF, Hajjar RJ, Rosenzweig A. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999;100: 2373-2379.
31. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ, Rosenzweig A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330-335.
32. Kurosu H, Maehama T, Okada T, Yamamoto T, Hoshino S, Fukui Y, Ui M, Hazeki O, Katada T. Heterodimeric phosphoinositide 3-kinase consisting of p85 and p110b is synergistically activated by the betagamma subunits of G proteins and phosphotyrosyl peptide. J Biol Chem. 1997; 272:24252-24256.
33. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, Meek S, Smith AJ, Okkenhaug K, Vanhaesebroeck B. The p110b isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110y. Proc Natl Acad Sci USA. 2008;105:8292-8297.
34. Krieg T, Qin Q, McIntosh EC, Cohen MV, Downey JM. ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am J Physiol. 2002;283:H2322-H2330.
35. Solenkova NV, Solodushko V, Cohen MV, Downey JM. Endogenous adenosine protects preconditioned heart during early minutes of reper-fusion by activating Akt. Am J Physiol. 2006;290:H441-H449.
36. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardio-protection. Cardiovasc Res. 2004;61:372-385.
37. Murphy E, Steenbergen C. Preconditioning: the mitochondrial connection. Ann Rev Physiol. 2007;69:51-67.
38. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res. 2002;55:534-543.
39. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K. Modulation of the mitochondrial permeability transition pore complex in GSK-3b-mediated myocardial protection. JMol Cell Cardiol. 2007;43:564-570.
40. Barber DF, Bartolome A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Ruckle T, Schwarz MK, Rodriguez S, Martinez A, Balomenos D, Rommel C, Carrera AC. PI3Ka inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med. 2005;11:933-935.
41. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gretener D, Perrin D, Leroy D, Vitte PA, Hirsch E, Wymann MP, Cirillo R, Schwarz MK, Rommel C. Blockade of PI3Ka suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005;11:936-943.